|
Malignant neoplasm of pancreas
|
0.320 |
Biomarker
|
disease |
CTD_human |
Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway.
|
19917848 |
2010 |
|
Malignant neoplasm of pancreas
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
In three cell lines (QG56 from lung cancer, T3M4 and Panc1 from pancreatic cancer), which produced both VEGF and FGF-2 at detectable levels, combined sVEGFR and sFGFR1 produced an enhanced inhibitory effect compared to their individual effects.
|
12136423 |
2002 |
|
Malignant neoplasm of pancreas
|
0.320 |
Biomarker
|
disease |
BEFREE |
Increased fibrosis and impaired intratumoral accumulation of macromolecules in a murine model of pancreatic cancer co-administered with FGF-2.
|
27080571 |
2016 |
|
Pancreatic Neoplasm
|
0.300 |
Biomarker
|
disease |
CTD_human |
Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway.
|
19917848 |
2010 |
|
Glioma
|
0.050 |
Biomarker
|
disease |
BEFREE |
We present a positive correlation between the autocrine expression of YY1 and TGF-beta 1, IGF-1 and FGF-2, known to be involved in the progression of gliomas and meningiomas.
|
19235591 |
2009 |
|
Glioma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
The regulator of fibroblast growth factor 2 (FGF-2) transcription (RFT) has been reported to be a transcriptional repressor of FGF-2 and induce glioma cell death by its overexpression.
|
15081425 |
2004 |
|
Glioma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Overexpression of FGF13 stabilized tubulin dynamics in vitro and knockdown of FGF13 decreased glioma invasion both in vitro and in vivo and prolonged overall survival of several xenograft models.
|
29059154 |
2018 |
|
Glioma
|
0.050 |
Biomarker
|
disease |
BEFREE |
In particular, we demonstrate that HMW FGF-2 has unique features in inhibiting glioma cell proliferation.
|
18930044 |
2008 |
|
Glioma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Reprogramming COX-2, mPGES-1 and CYP4A mediated-AA metabolism in glioma by flavonoid ISL inhibits the angiogenic Akt- FGF-2/TGF-β/VEGF signaling through ceRNA effect of miR-194-5p and lncRNA NEAT1, and may serve as a novel therapeutic strategy for human glioma.
|
31438982 |
2019 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
Tubes contained either growth factor-reduced basement membrane extract (BME)-alone (negative control) or BME-containing vascular endothelial growth factor (VEGF)-D (positive control for lymphangiogenesis) or FGF-2/VEGF-A (positive control for angiogenesis) or a high VEGF-D-expressing breast cancer cell line MDA-MD-468LN (468-LN), or VEGF-D-silenced 468LN.
|
23711825 |
2013 |
|
Malignant neoplasm of breast
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
To test the implicated role of basic fibroblast growth factor (bFGF; FGF-2) in promoting differentiation in breast cancer, we enforced the expression of FGF-2 in T-47D breast cancer cells.
|
11027671 |
2000 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
Aquaporin3 is required for FGF-2-induced migration of human breast cancers.
|
23468877 |
2013 |
|
Malignant neoplasm of breast
|
0.040 |
Biomarker
|
disease |
BEFREE |
Deletion of Fgf13 in a MMTV-PyMT breast cancer cell line reduces colonization of the lungs in a tail vein injection.
|
31341204 |
2019 |
|
Colorectal Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Furthermore, the xenograft model indicated that miR-10b inhibited CRC cell growth and lung metastasis in vivo by targeting fibroblast growth factor 13 (FGF13).
|
30720165 |
2019 |
|
Colorectal Carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Increased lymphatic vascular density is seen before colorectal cancers reach stage II and growth factor FGF-2 is downregulated in tumor tissue compared with normal mucosa.
|
19245594 |
2009 |
|
Colorectal Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
In this study, we examined whether recombinant human KGF (rhKGF) induces major angiogenic growth factors including VEGF-A, FGF-2 and hepatocyte growth factor (HGF) in human colorectal cancer cells (HCT-15), which express a high level of KGFR, but a low or negligible level of KGF. rhKGF significantly increased the VEGF-A expression level in a serum-free medium of HCT-15 cells, but FGF-2 and HGF expression levels were too low to detect.
|
19148469 |
2009 |
|
Colorectal Carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
Fibroblast surface-associated FGF-2 promotes contact-dependent colorectal cancer cell migration and invasion through FGFR-SRC signaling and integrin αvβ5-mediated adhesion.
|
25973543 |
2015 |
|
Malignant neoplasm of prostate
|
0.040 |
Biomarker
|
disease |
BEFREE |
FGF-2 disrupts mitotic stability in prostate cancer through the intracellular trafficking protein CEP57.
|
23243019 |
2013 |
|
Malignant neoplasm of prostate
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Several PCa cell lines showed increased FGF13 expression at the mRNA and protein levels compared to the immortalized prostate epithelial cell line PNT1a.
|
26891277 |
2016 |
|
Malignant neoplasm of prostate
|
0.040 |
Biomarker
|
disease |
BEFREE |
These studies establish that endogenous FGF-2 dominantly regulates prostate cancer cell survival and proliferation and that exogenous FGFs may assume this function in the absence of endogenous FGF-2.
|
15561781 |
2004 |
|
Malignant neoplasm of prostate
|
0.040 |
Biomarker
|
disease |
BEFREE |
FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer.
|
29887238 |
2018 |
|
Prostate carcinoma
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Several PCa cell lines showed increased FGF13 expression at the mRNA and protein levels compared to the immortalized prostate epithelial cell line PNT1a.
|
26891277 |
2016 |
|
Prostate carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
These studies establish that endogenous FGF-2 dominantly regulates prostate cancer cell survival and proliferation and that exogenous FGFs may assume this function in the absence of endogenous FGF-2.
|
15561781 |
2004 |
|
Prostate carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
FGF-2 disrupts mitotic stability in prostate cancer through the intracellular trafficking protein CEP57.
|
23243019 |
2013 |
|
Prostate carcinoma
|
0.040 |
Biomarker
|
disease |
BEFREE |
FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer.
|
29887238 |
2018 |